CRO & Medicinal Chemistry
Fibrosis R&D
KOL & Clinic Trials
KOL & Strategic Leadership
AI Drug Development
KOL & Cancer R&D
Industry Leading Small Molecule SMAD Signaling Therapeutics
First-In-Class IP Secured & AI Supported : Anti-Cancer • Anti-Fibrosis • Combination Therapeutics
IP: We Lead In Small Molecule SMAD Signaling Coverage
DOMINANT
GLOBAL IP
Worldwide coverage for small molecule SMAD3 inhibition is secured for anti-cancer, anti-fibrosis, and combination product use. Product marketspace footprint totals more than $125 Billion annually and includes US, EU, China, India and all other major global markets.
CANCER IP
Coverage is granted for more than 10 specific cancers with further global MoA rights for any small molecule SMAD3 product use including combination therapeutic applications with approved products already in market. Worldwide coverage includes US markush claims.
FIBROSIS IP
Therapeutic novelty confirmed with global rights for small molecule SMAD3 inhibition. MoA includes combination therapeutic applications. Product advanced as the only small molecule SMAD inhibitor secured for fibrosis.
DOMINANT
GLOBAL IP
Worldwide coverage for small molecule SMAD3 inhibition is secured for anti-cancer, anti-fibrosis, and combination product use. Product marketspace footprint totals more than $125 Billion annually and includes US, EU, China, India and all other major global markets.
CANCER IP
Coverage is granted for more than 10 specific cancers with further global MoA rights for any small molecule SMAD3 product use including combination therapeutic applications with approved products already in market. Worldwide coverage includes US markush claims.
FIBROSIS IP
Therapeutic novelty confirmed with global rights for small molecule SMAD3 inhibition. MoA includes combination therapeutic applications. Product advanced as the only small molecule SMAD inhibitor secured for fibrosis.
Products: Our Therapeutics Have First-in-Class Applications
CANCER THERAPY
Small molecule Smad3 inhibition prevents phosphorylation & tumorigenesis by regulating DNA binding, and transcription. Anti-cancer efficacy occurs without common toxicity profiles associated with large molecules or fusion proteins that directly target TGF-β pathway inhibition.
FIBROSIS THERAPY
Our small molecule SMAD3 MoA demonstrates downstream efficacy on the heterogeneous SMAD complex regulating fibrosis. Results show anti-fibrosis activity comparable to certain large molecules already in market, without TGF-β pathway inhibition associated with toxicity.
COMBINATION THERAPIES
Preclinical studies with approved medicines suggest improved results when combined with our SMAD3 products. These studies predict that our small molecule inhibitors are effective as a single use product and can also be combined for use with known therapeutics.
CANCER THERAPY
Small molecule Smad3 inhibition prevents phosphorylation & tumorigenesis by regulating DNA binding, and transcription. Anti-cancer efficacy occurs without common toxicity profiles associated with large molecules or fusion proteins that directly target TGF-β pathway inhibition.
FIBROSIS THERAPY
Our small molecule SMAD3 MoA demonstrates downstream efficacy on the heterogeneous SMAD complex regulating fibrosis. Results show anti-fibrosis activity comparable to certain large molecules already in market, without TGF-β pathway inhibition associated with toxicity.
COMBINATION THERAPIES
Preclinical studies with approved medicines suggest improved results when combined with our SMAD3 products. These studies predict that our small molecule inhibitors are effective as a single use product and can also be combined for use with known therapeutics.
AI: We Have A Strategic & Technical Development Advantage
AI MARKET FOCUS
We fall within the $500 Billion US Stargate AI infrastructure plan seeking AI supported cancer solutions. Stargate earmarks support for AI-driven anti-cancer therapies, in recognition of the strategic importance of AI in drug discovery. We deploy AI drug design and analysis to accelerate our progress.
AI DRUG
DESIGN
Our LLM powered protein heterotrimer enables digital and optical conformational space exploration of uncharted PPI SMAD structures that interact with our molecules. This expedites drug design & analysis, advancing testing for faster FDA approvals with less costly study protocols.
AI SMAD SCAFFOLD
Our AI platform has created a SMAD scaffold for emulating molecular activity and reactions. We actively use this tool to identify, test, and configure target emulations in a dynamic setting that includes, drug design, study planning, and patient reviews.
AI Market Focus
We fall within the $500 Billion US Stargate AI infrastructure plan seeking AI supported cancer solutions. Stargate earmarks support for AI-driven anti-cancer therapies, in recognition of the strategic importance of AI in drug discovery. We deploy AI drug design and analysis to accelerate our progress.
AI DRUG
DESIGN
Our LLM powered protein heterotrimer enables digital and optical conformational space exploration of uncharted PPI SMAD structures that interact with our molecules. This expedites drug design & analysis, advancing testing for faster FDA approvals with less costly study protocols.
AI SMAD SCAFFOLD
Our AI platform has created a SMAD scaffold for emulating molecular activity and reactions. We actively use this tool to identify, test, and configure target emulations in a dynamic setting that includes, drug design, study planning, and patient reviews.
Senior Leadership: Our Team Have A Successful Record
BIOTECH & AI
Our science team boasts over 45 FDA IND approvals. Team includes our CSO with a Big Pharma resume, a top 5 CRO overseeing IND & Ph.1 trials, KOL expertise from the National Cancer Foundation, and top oncology R&D centres in the US, backed by a leading AI drug discovery platform.
BUSINESS STRATEGY
Mr. Anthony Desir heads business strategy as a founder, director, and major shareholder with his 40-year background in corporate advisory finance. His clients include senior leadership at bulge bracket banks, major conglomerates, and government bodies across a variety of industrial sectors.
TECHNICAL PLANNING
Dr. Timothy Letters directs technical planning as a founder, director and major shareholder with his distinguished background in IP Law. He has filed 1000’s of successful patents and is a strategic advisor to a number of medical councils, hospitals, universities and government bodies in multiple countries.
BIOTECH & AI
Our science team boasts over 45 FDA IND approvals. Team includes our CSO with a Big Pharma resume, a top 5 CRO overseeing IND & Ph.1 trials, KOL expertise from the National Cancer Foundation, and top oncology R&D centres in the US, backed by a leading AI drug discovery platform.
BUSINESS STRATEGY
Mr. Anthony Desir heads business strategy as a founder, director, and major shareholder with his 40-year background in corporate advisory finance. His clients include senior leadership at bulge bracket banks, major conglomerates, and government bodies across a variety of industrial sectors.
TECHNICAL PLANNING
Dr. Timothy Letters directs technical planning as a founder, director and major shareholder with his distinguished background in IP Law. He has filed 1000’s of successful patents and is a strategic advisor to a number of medical councils, hospitals, universities and government bodies in multiple countries.
Partnerships
© 2025 MOEXA Inc. All Rights Reserved.